Heart failure and managed care: Clinical characteristics and quality of drug therapy

Drug Benefit Trends

Volumn 17, Issue 12, 2005, Pages 571-580

  Dutro, Michael P ^a   Koo, Yuri H ^a   Koren, Andrew T ^a   Cattaneo, Michael J ^a   Foody, JoAnn M ^b   Goldberg, George A ^c  

^a PFIZER INC   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c i3 Magnifi   (United States)

Author keywords

Drug therapy; Facilities services utilization; Heart failure; Managed care; Quality of care

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYPOCHOLESTEROLEMIC AGENT; NITRATE; POTASSIUM; SPIRONOLACTONE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTHRITIS; ARTICLE; BILLING AND CLAIMS; CARDIOMEGALY; CARDIOMYOPATHY; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE DEFECT; COMORBIDITY; DATA BASE; DEPRESSION; EVALUATION; FEMALE; FLUID RETENTION; GYNECOMASTIA; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MORBIDITY; MORTALITY; PERIPHERAL VASCULAR DISEASE; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; STROKE; UNITED STATES;

EID: 33750816178     PISSN: 10805826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. American Heart Association. Heart Disease and Stroke Statistics-2005 Update. Dallas: American Heart Association; 2005:26-27.
2. Z American Heart Association. The causes of heart failure. Available at: www.americanheart.org/presenter.jhtml?identifier=324. Accessed November 4, 2005.
3. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). American College of Cardiology Web site. Available at: www.acc.org/clinical/guidelines/failure/index.pdf. Accessed November 3, 2005.
4. O'Connell JB. The economic burden of heart failure. Clin Cardiol. 2000;23(suppl III).III-6-III-10.
5. American Heart Association. Heart Disease and Stroke Statistics-2004 Update. Dallas: American Heart Association; 2004.
6. Arias E, Anderson RN, Kung HC, et al. Deaths: final data for 2001. Natl Vital Stat Rep. 2003;52(3):1-115.
7. Welch WP, Beigsten C, Cutler C, et al. Disease management practices of health plans. Am J Manag Care. 2002;8:353-361.
8. National Center for Health Statistics, Centers for Disease Control and Prevention. International Classification of Diseases, Ninth Revision, Clinical Modification. Available at: www.cdc.gov/nchs/datawh/ftpserv/ftpicd9/ftpicd9.htm. Accessed November 14, 2005.
9. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-776.
10. Demers C, McMurray JJ, Swedberg K, et al. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA. 2005;294:1794-1798.
11. Pfeffer MA, Swedberg K, Granger CB, et al, for the CHARM Investigators and Committees. Ef fects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-766.
12. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110:588-636.
13. Anton C, Cox AR, Watson RD, Ferner RE. The safety of spironolactone treatment in patients with heart failure. J Clin Pharm Ther. 2003;28:285-287.
14. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
15. DTEC Claims analysis tool version 3.0. Pfizer Inc; 2004.
16. English MA, Mastrean MB. Congestive heart failure: public and private burden. Crit Care Nurs Q. 1995;18:1-6.
17. Ni H. Prevalence of self-reported heart failure among US adults: results from the 1999 National Health Interview Survey. Am Heart J. 2003;146:121-128.
18. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol. 1999;83(2 suppl 1):1A-38A.
19. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials [published correction in JAMA. 1995;274: 462]. JAMA. 1995;273:1450-1456.
20. Lechat P, Packer M, Chalon S, et al. Clinical effects of β-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation. 1998;98:1184-1191.
21. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
22. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533.
23. Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
24. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol. 1996;78:902-907.
25. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007-2018.
26. Wlodarczyk JH, Keogh A, Smith K, McCosker C. CHART: Congestive Cardiac Failure in Hospitals, an Australian Review of Treatment. Heart, Lung and Circulation. June 2003;12:94-102.
27. Sloane PD, Gruber-Baldini AL, Zimmerman S, et al. Medication undertreatment in assisted living settings. Arch Intern Med. 2004;164:2031-2037.
28. Jencks SF, Cuerdon T, Burwen DR, et al. Quality of medical care delivered to Medicare beneficiaries: a profile at state and national levels. JAMA. 2000;284:1670-1676.
29. Everly MJ, Heaton FC, Cluxton RJ Jr. β-Blocker underuse in secondary prevention of myocardial infarction. Ann Pharmacother. 2004;38:286-293.
30. Bungard TJ, McAlister FA, Johnson JA, Tsuyuki KT. Underutilisation of ACE inhibitors in patients with congestive heart failure. Drugs. 2001;61:2021-2033.
31. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41:211-214.
32. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol. 2004;44:810-819.
33. Gustafsson F, Arnold JM. Heart failure clinics and outpatient management: review of the evidence and call for quality assurance. Eur Heart J. 2004;25:1596-1604.
34. Whellan DJ. Heart failure disease management: implementation and outcomes. Cardiol Rev. 2005;13:231-239.